Irene Brinker CEO & Co-Founder of SenceTech, CCO of Planexta, Inc.
Cardiovascular diseases are the most prominent causes of death globally. Reports suggest that an estimated 18.5 million people die annually due to undiagnosed or unmanaged cardiovascular diseases, representing over 40 percent of all global deaths. Preventive care for heart diseases has become increasingly necessary but there is still a lack of medically accurate technologies for prenosological diagnostics.
On a mission to save lives through a connected health solution that solves for this growing healthcare crisis, SenceTech and partner Planexta Inc., a rapidly emerging biotech company developing robust healthcare technologies, is introducing a novel and potentially life-saving product—a unique, one wrist electrocardiogram (ECG) sensor for constant Heart Rate Variability (HRV) monitoring engineered as a wearable solution. It’s called SenceBand.
Irene Brinker, CEO of SenceTech says, “Our patent-pending, first of its kind, constant monitoring ECG and HRV technology for one wrist has the potential to truly affect long-term health outcomes by helping consumers understand how their daily behaviors affect their long-term health and learn to take action to dramatically decrease their risks of developing chronic conditions in the future”
SenceBand, powered by Planexta’s patent-pending combination of ECG and PPG sensors which, unlike traditional ECG machines, that allows for accurate tracking of heart behaviors on-the-go has already been awarded 2 CES Honors for innovation in biotechnology, sports, fitness & wearables. Sence isolates and magnifies the R-peaks in a QRS complex to provide a clear picture of heart rate variability, stress levels, recovery rates and emotional states.
In many cases, health problems including obesity, diabetes, cancer, depression or anxiety, IBS, and even allergies can be triggered or amplified due to extended periods of heightened stress levels which can be effectively monitored and managed using this device.
Our mission is to save lives - We develop our technologies to fulfill our mission
Further, SenceBand recognizes an extensive range of human emotions allowing users a deeper understanding of themselves and their emotional health. Brinker explains that SenceBand can also make a huge impact in mental health programs as Sence can be used as a monitoring device to understand a patient’s emotional progressions, allowing for deeper dive sessions to decipher the reason behind emotional triggers without relying on the patient’s memory to uncover them. “There are endless possibilities in which SenceBand can assist diverse areas of care,” she mentions. “Most people don’t understand how interconnected all of these things are. What you eat, how you feel, how you sleep—all of these things affect your overall wellbeing and risk potential for developing chronic conditions in the future. Our ultimate goal is to create an ecosystem where both patients and doctors feel more aware and empowered to facilitate better preventive care,” says Brinker.
HRV is an established method of monitoring for numerous health parameters including: cardiovascular, respiratory, muscular, nervous, and glandular systems, emotional states, immunity factors, stress levels and responses, circadian rhythms, signs of aging, and more. “HRV is essentially a window into the body’s overall health and wellbeing.”
As the first comfortable constant monitoring device able to capture accurate ECG and HRV data, SenceBand can provide doctors insight into their patients daily lives, experiences, and physiological responses as opposed to a one-time reading at the doctor’s office. In fact, the patient can even upload their SenceBand readings directly to Precise, Planexta’s cloud-based medical ECG/HRV translation platform (currently in Beta) to share detailed analysis with their chosen medical professionals and allow for more detailed information to aid in diagnosis.
“In the future, with the addition of our constant blood pressure monitor (in Beta,) and blood oxygenation level readers, we hope to use the combination of these technologies to mitigate up to 80% of cardiovascular risks. We believe that the future combination of our technologies will be able to detect and predict ischemia and type 2 myocardial infarction up to an hour prior to an event and alert the wearer and their medical care providers so they can take immediate action” Brinker concludes.